IMPORTANCE Increases in prescription opioid use in the United States have been attributed to changing prescribing guidelines and attitudes toward pain relief; however, the spread of opioid use within households through drug diversion may also be a contributing factor.
scription opioids also caused more than 5000 ER visits among children 5 years or younger in 2011, which underscores the harms of the broad availability of opioids in US households. 15 Opioids are often prescribed in doses exceeding clinical guidelines for patients with non-cancer-related pain, 16 and in large quantities, resulting in surpluses of opioids stored in household medicine cabinets. 17 Unused medications create opportunities for nonprescribed use and drug sharing among friends and family members, who may perceive these medications to be low risk given their storage at home. 18 For example, a third of veterans receiving prescription opioid therapy report sharing unused medications with family members, 18 and more than 70% of non-medical opioid users obtain the drugs from family members and friends. 19, 20 Because prescription medication sharing is common, 21 families and other social networks likely shape norms and behaviors surrounding the use of prescription opioids. Given the documented spread of substance use behaviors, such as heavy drinking within social networks, [22] [23] [24] [25] it is likely that prescription opioid use can also spread within networks, such as families. Although a previous study has examined the association between opioid abuse in one person and opioid abuse in another, 26 the extent to which prescribed opioid use in one person is associated with increased risk of prescribed opioid use in another person remains unknown. We quantified the association between potential access to opioids resulting from a new prescription started by a household member and subsequent new use of prescription opioids by other family members. Specifically, we compared the 1-year risk of opioid initiation due to the introduction of prescription opioids vs introduction of nonopioid analgesics (prescription nonsteroidal anti-inflammatory drugs [NSAIDs] ) in households of commercial insurance beneficiaries that included employees, spouses, and dependents (hereinafter, opioid households and NSAID households). We further explored whether associations varied across subgroups of age, geographic region, potential indications, refill availability, days' supply, and by year and opioid dose.
Methods
We used the 2000-2014 Truven Health Analytics MarketScan Commercial Claims and Encounters databases covering the years 2000 to 2014. MarketScan contains standardized, deidentified, person-level information on enrollment, paid inpatient and outpatient services and procedures, and outpatient pharmacy dispensing claims of employer-sponsored commercial insurance beneficiaries, their spouses, and dependents. MarketScan is one of the largest, fully integrated, and most complete commercial insurance claims databases available for the United States, where beneficiaries can be tracked across insurance plans, health care sites, clinician types, and over time 27 with median follow-up of 3 years. The database increased from 3.7 million enrollees to 47.2 million from 2000 to 2014. The Office of Human Research Ethics at the University of North Carolina at Chapel Hill deemed the study exempt from review.
Study Population
This retrospective cohort study included household members of patients who initiated use of prescription opioids or prescription NSAIDs based on outpatient pharmacy dispensing claims (henceforth, we refer to the index patient as "Patient 0"). Prescription NSAIDs were chosen as the active comparator group because they have similar indications for treating pain, which minimizes the potential for unmeasured confounding. New use was defined as the first pharmacy dispensing claim after a 365-day period of continuous enrollment without evidence of prescription opioid or prescription NSAID use in claims. We generalized the "new-user" design 28 to "new households" by requiring all household members to have continuous prescription drug coverage with no record of prescription opioid or NSAID use during the baseline period. Household members entered either the opioid or NSAID cohort at the index date anchored to the date of initiation by Patient 0. Eligible index dates were those occurring between January 1, 2001, and December 31, 2014, to ensure observation of the 1-year baseline. To make comparisons between cohorts more rigorous and identify index patients with similar indications, household members of patients who had a diagnosis of malignant neoplasm, used hospice services during the baseline period, or initiated both prescription opioids and NSAIDs on the same day were excluded.
Opioid Medication Exposure
Pharmacy dispensing billing claims for the most commonly prescribed synthetic and semisynthetic opioids and NSAIDs were identified in the Outpatient Pharmaceutical Claims file by their generic string name. Opioids and NSAIDs were restricted to oral and transdermal formulations (see eTable 1 in the Supplement). We excluded claims for opioids used primarily to treat Parkinson disease (apomorphine), opioid dependence (methadone), and cough (potassium guaiacolsulfonate-hydrocodone bitartrate).
Outcome Assessment
Our primary outcome was initiation of prescription opioids by members of the index patient's household. Initiation by a household member was assessed similarly to cohort eligibility defined by Patient 0 using the dispensing date for an eligible opioid in the Outpatient Pharmaceutical claims database.
Covariates
Baseline covariates for household members were assessed during the year prior to the index date defined by Patient 0. Potential confounders of the association between opioid receipt in Patient 0 and opioid initiation by household members were identified a priori using subject matter knowledge and causal diagrams, 29 and included household size, composition (children <18 years, yes/no), region of residence (Northeast, North Central, South, West), calendar year of cohort entry, and history of substance use diagnosis for Patient 0 (yes/ no). Baseline predictors of loss to follow-up (defined as disenrollment) and opioid initiation of at-risk household members included age, sex, history of chronic pain diagnosis, psychiatric comorbidity (dichotomous variables for yes/no), health care utilization (number of outpatient visits, continuous; emergency department visit in prior 7 or 30 days, yes/no), and use of scheduled prescription medications (dichotomous variables for yes/no for each drug class; see eTable 1 in the Supplement for definitions).
Statistical Analyses
We estimated the 1-year risk of opioid initiation by household members (excluding Patients 0) within each treatment group using the complement of the Kaplan-Meier estimator with time in days from the index date. Household members were individually censored at the earliest of an event, at 1 year of followup, disenrollment, or administrative censoring on December 31, 2014. We estimated 1-year risks and risk differences (RDs) for opioid initiation using inverse probability-weighted KaplanMeier estimators adjusting for baseline confounders, prognostic factors, and dropout. 30 Weights were the product of inverse probability of treatment and inverse probability of censoring weights (see the eMethods in the Supplement for details on the construction of weights). Age, number of outpatient visits during baseline, and household size were modeled using restricted quadratic splines 31 and calendar year as a cat- We performed 2 sensitivity analyses. First, the primary analysis was performed after restricting to 2-adult (age >18 years) households to account for shared genetic factors that could give rise to opioid-seeking behavior. Second, we assessed the extent to which unmeasured differences between the opioid and NSAID cohorts could explain our results. 34, 35 Additional details are provided in the eMethods in the Supplement. All analyses were conducted using SAS statistical software (version 9.4; SAS Institute Inc).
Results

Characteristics of the Study Sample
The study sample comprised 12 695 280 members of 5 871 003 opioid households and 6 359 639 members of 3 015 932 NSAID households, after excluding 84 810 households (1%) without information on geographic region (Figure 1 ). Opioid and NSAID households were of similar size (median, 3 enrollees; interquartile range [IQR], 2-4 enrollees), but opioid households were more likely to reside in the South than NSAID households ( Table 1) . Demographic characteristics were similar between cohorts: the median age of household members was 22 years (IQR, 11-45 years), and less than half were female. Overall, baseline covariates were balanced between household exposure groups. However, compared with members of NSAID households, slightly greater proportions of members of opioid households had used attention-deficit/hyperactivity disorder medications, antibiotics, benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), and sleep medications, but not β-blockers, statins, or muscle relaxants during baseline. Members of opioid households were also more likely than members of NSAID households to have a history of back and neck pain, migraine, fractures, depression, substance abuse, and cancer screening, and less likely to have diabetes mellitus and arthritis. However, utilization of outpatient and inpatient services and emergency department visits were similar between household exposure groups.
Unadjusted Analysis
Members of opioid households and NSAID households were followed for a median of 1 year (IQR, 0.6-1.0-year). During 14 846 450 person-years of follow-up, 1 786 014 individuals initiated use of prescription opioids and 4 187 048 individuals disenrolled from their health plan (21% in NSAID households, 22% in opioid households). Overall, the 1-year risk of prescription opioid initiation by a second household member was 11.32% (95% CI, 11.30%-11.34%). The 1-year unadjusted risk of prescription opioid initiation was 11.68% (95% CI, 11.66%-11.70%) within opioid households and 10.60% (95% CI, 10.57%-10.63%) within NSAID households.
Inverse Probability-Weighted Analysis
All potential confounders and predictors of opioid initiation or dropout identified a priori were included in corresponding propensity score models for treatment and censoring weights. The means of the treatment and censoring weights were 1.00 (range, 0.36-6.06) and 0.98 (range, 0.36-3.59), respectively. Cumulative incidence curves for opioid initiation over 1 year of follow-up by household opioid availability are presented in Figure 2 . The 1-year risk of opioid initiation was 11.83% (95% CI, 11.81%-11.85%) among individuals in an opioid household, compared with 11.11% (95% CI, 11.09%-11.14%) among individuals in an NSAID household ( Table 2 ). The adjusted 1-year RD in opioid initiation due to potential access to household opioids was 0.71% (95% CI, 0.68%-0.74%).
Subgroup Analyses
The association between household opioid availability and opioid initiation varied across subgroups of age, geographic region, and potential indication of Patient 0 ( Results varied across characteristics of the index prescription ( Table 3) . The RD for opioid initiation was 0.53% (95% CI, 0.49%-0.57%) in households where the index supply was less than 30 days, compared with 1.14% (95% CI, 0.97%-1.34%) in households with at least a 30-day supply. The RD was 0.44% (95% CI, 0.40%-0.47%) in households with a single fill of the index prescription, compared with 1.43% (95% CI, 1.33%-1.53%) in households with refills. Compared with NSAID households, the RD for opioid initiation in households with an index opioid prescription for less than 20 MME/d was 1.44% (95% CI, 1.39%-1.50%), 0.81% (95% CI, 0.77%-0.85%) for 20-50 MME/d, 0.78% (95% CI, 0.72%-0.83%) for 51-89 MME/d, and 1.02% (95% CI, 0.95%-1.07%) for ≥90 MME/d. Risk differences did not vary appreciably over the years of the study (see eFigures 1 and 2 in the Supplement).
Sensitivity Analyses
In 2-adult households (n = 2 706 922), an opioid prescription to 1 adult was associated with increased risk of opioid initiation in the other (RD, 1.08% [95% CI, 0.90%-1.39%]). Although we controlled for a number of potential confounders, we also assessed the sensitivity of our findings to unmeasured baseline differences between the opioid and NSAID groups (eTable 2 in the Supplement). We found that an unmeasured confounder that is modestly associated with the exposure (eg, prevalence difference = 0.9%) and the outcome (eg, RD = 0.9) after adjustment for all measured variables could explain our observed estimate of the RD (0.71%). Alternative scenarios are presented in eTable 2 in the Supplement.
Discussion
We conducted a large, retrospective, cohort study comparing the risk of opioid initiation among commercial insurance beneficiaries who were newly exposed to prescription opioids vs prescription NSAIDs through a household member's prescription. We observed a 0.71% absolute higher 1-year risk of prescription opioid use among individuals in opioid households compared with prescription NSAID households, which could reflect increased access to these products or unmeasured risk factors. Associations varied across age, region, potential indication, and characteristics of the index prescription.
Previous studies on prescription opioids have used MarketScan, 36-39 but none examined patterns of use within families. Prior research within families focused on disentangling genetic vs environmental transmission of drug abuse 25 ; however, opiate abuse can develop from opioids prescribed for pain management. 40 Because medication sharing cannot be captured in administrative data, understanding patterns of prescribed opioid use within households may be a critical first step toward addressing the opioid epidemic. If associations across households and social networks are validated in future studies, even small risk differences may be relevant on a population level, considering the broad environmental availability of prescription opioids.
We assessed whether our results could be explained by potential unmeasured differences between members of opioid and NSAID households in sensitivity analyses. Unmeasured variables include whether household members see the same health care professional with a preference for prescribing opioids. We found that the magnitude of such an effect need not be large to explain our findings. A previous study estimated physician preference for prescribing the same analgesic to be more than 20%
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; thus, it is plausible that our results could be explained by unmeasured health care professional preference if household members see the same provider (eg, physician, dentist). Alternatively, unmeasured environmental or system-level factors or household socioeconomic status may have given rise to confounding.
34
The association between potential access to household opioids and opioid initiation could be explained by multiple mechanisms. First, family members may share their medications with other members, which may lead to one seeking his Opioid household
NSAID household
Estimates adjusted for household size, region, year of cohort entry, family history of substance abuse, age, sex, baseline pain and psychiatric co-morbidities, use of scheduled and unscheduled prescription medications, and health care utilization. NSAID indicates nonsteroidal anti-inflammatory drug.
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Household Opioid Availability and Prescription Opioid Initiation or her own prescription. Second, household opioid use may shape attitudes and norms of opioid use. 26 Third, spousal correspondence of opioid use may be due to homophily, which is defined as the inclination of similar individuals to associate.
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Although we could not disentangle potential mechanisms, interventions that address the opioid epidemic could include initiatives promoting safe medication storage within households and safe disposal of unused medications. Clinicians may need to consider the context within which medications will be used to assess the risks and benefits of prescribing opioids. For certain patients, prescribing in smaller quantities or without refills may help mitigate the risk of subsequent opioid use by a household member.
Strengths and Limitations
We generalized the "new-user" design 28 to leverage information on households in large administrative databases and restrict to enrollees who had no prior access to opioids or NSAIDs in the household. The benefit of our "new-household" approach is the exclusion of households with prevalent use of prescription opioids, which may be affected by differential attrition, adherence, physiologic adaptation, or early adverse effects. 28 We used households with prescription NSAIDs as an active comparator group to contextualize households with prescription opioids, which have similar indications and minimize potential bias owing to differential allocation of opioids to certain patients. However, restriction to households limits the generalizability of our inferences and applicability to realworld pharmacotherapy decisions. Moreover, MarketScan oversamples the South and has poor coverage of the West; thus, our study may not directly generalize to the US commercially insured population. Despite our attempt to improve the internal validity of our estimates, we could not verify coresidence of household members or other sources of opioids, such as coresidents with public insurance or another health plan. Misclassification of prior exposure could introduce prevalent user bias, whereas underascertainment of true events will bias the RD even with perfect specificity and nondifferential sensitivity. 43 Other databases with residential addresses to link patients or with clinician or system characteristics could help address exposure and outcome misclassification. The cohort and primary outcome were identified using pharmacy dispensing billing claims. Electronic pharmacy dispensing claims are considered the gold standard of prescription drug exposure compared with self-reported medication use or outpatient medical records because insurance reimbursement is based on complete and accurate claims. 44 Although opioids paid for in cash or received in inpatient settings were not captured in our data, approximately 15% of opioid prescriptions in 2008 were paid for in cash 45 and 90% of opioids are dispensed from retail pharmacies. 46 Similarly, pharmacy dispensing billing claims were used to identify prescription NSAIDs. Although we expect the sensitivity of prescription NSAID exposure to be high, we lack information on over-the-counter (OTC) NSAID use. However, OTC NSAID exposure is not expected to be a substantial source of bias in our study because sensitivity analyses have shown that prescription claims data can provide valid estimates of drug-outcome associations even when a large proportion of drug use is OTC.
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Conclusions
Although we cannot rule out shared risk factors, such as clinician preference, prescription drug monitoring, or genetic predilection, our results suggest that opioid prescribing decisions may need to take into account the context within which medications will be used and the potential risk of subsequent opioid initiation by other individuals. Addressing the opioid use epidemic will require comprehensive solutions for all aspects contributing to this public health issue, including the potential for medication sharing and other unintended consequences of prescription opioid use in households. Author Contributions: Dr Seamans had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Prevalence difference (PD) per 100 enrollees of unmeasured confounder across levels of household opioid availability. Risk difference (RD) per 100 enrollees estimating the association between an unmeasured confounder and opioid initiation within all inverse probability weighted strata. Observed inverse probability weighted risk difference of 0.71 per 100 enrollees and confidence limits corrected by bias terms that are the product of the PD and RD. Estimates adjusted for household size, region, year of cohort entry, family history of substance abuse, age, sex, baseline pain and psychiatric comorbidities, use of scheduled and unscheduled prescription medications, and health care utilization. MME indicates morphine milligrams equivalent.
eMethods for Constructing inverse probability of treatment weights (IPTW) and inverse probability of censoring weights (IPCW)
We used inverse probability weighted Kaplan Meier estimators to approximate a study where household members were randomized at baseline to be exposed to household opioids or household NSAIDs. Weights were the product of inverse probability of treatment and inverse probability of censoring weights that were estimated using logistic regression models. The model for the treatment weights included confounders and prognostic factors. The model for the censoring weights included predictors of disenrollment (i.e., dropout). Age, number of outpatient visits during baseline, and household size were modeled using restricted quadratic splines 31 and calendar year as a categorical variable with each year as a separate category. Treatment weights were calculated as the complement of the propensity score (PS) for members of opioid households and (1-PS) for members of NSAID households and stabilized by the marginal probability of household exposure to opioids in the cohort. Censoring weights were calculated as the complement of the probability of dropout (Pr(D)) for those who disenrolled, and (1-Pr(D)) for those who remained under observation and stabilized by the marginal probability of disenrollment in the cohort.
eMethods for Sensitivity Analysis to Assess Potential Influence of Unmeasured Confounder.
We examined the potential influence of an unmeasured confounder (e.g., socioeconomic status, healthcare provider, or prescription drug monitoring) by applying bias formulas under simplifying assumptions. 1 Assuming homogeneity of the prevalence difference of an unmeasured binary confounder between household exposure groups in all inverse probability weighted strata, and homogeneity of the difference in opioid initiation risk between levels of the confounder within all inverse probability weighted strata, we evaluated a range of bias factors that could potentially reduce our observed risk difference for the household opioid availability-opioid initiation relationship (0.71%) to the null. Bias factors were applied to bootstrapped samples to obtain 95% confidence limits.
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